Loading...
XASX
PGC
Market cap285mUSD
Dec 05, Last price  
0.26AUD
1D
4.00%
1Q
-18.75%
Jan 2017
-67.51%
Name

Paragon Care Ltd

Chart & Performance

D1W1MN
XASX:PGC chart
P/E
51.35
P/S
0.14
EPS
0.01
Div Yield, %
Shrs. gr., 5y
7.47%
Rev. gr., 5y
65.94%
Revenues
2.97b
+865.41%
249,584699,128371,060100,6231,126,2828,306,59314,661,39115,718,56617,096,44719,416,93132,223,35193,383,052117,192,924117,200,000236,009,000231,689,000235,840,000237,618,000307,630,0002,969,885,000
Net income
8m
-22.11%
-1,645,578-1,401,723-1,257,509-1,846,270-355,832147,782851,183-77,484739,6031,084,8912,103,1567,530,52310,174,76110,950,5558,862,000-77,269,0008,279,0006,634,00010,760,0008,381,000
CFO
44m
+150.45%
-2,058,209-1,281,847-1,000,453-591,329-432,699235,190145,752-310,749725,543-2,085,690809,8747,759,22111,989,3807,559,0001,158,0005,287,00027,463,00019,032,00017,749,00044,452,000
Dividend
Sep 18, 20230.006 AUD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Paragon Care Limited supplies durable medical equipment, medical devices, and consumable medical products to health and aged care markets in Australia, New Zealand, and internationally. The company offers clinical solutions for anaesthetists, intensivists, cardiac, vascular, and pain management; designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohaematology laboratories; and eye care products, such as ophthalmology and optometry, neonatal vision screening, and procedural kits. It also provides neonatal and paediatric assessment and treatment, including newborn hearing and vision screening, jaundice management, targeted temperature management, cerebral function monitoring, and seizure detection, as well as pain management and enteral feeding solutions; surgical products for hip and knee arthroplasty, infection prevention, pain management, biologics, and the operating room; and equipment repair and maintenance services. In addition, the company offers sterilisable transducers for surgical procedures such as neurology, hepatobiliary, renal, colorectal, vascular, laparoscopic, and robotic procedures; ultrasound systems, shockwave therapy, lasers, and accessories for infection control; and veterinary products, including point-of-care diagnostics, therapeutic lasers, oncology delivery products, centrifuges, autoclaves, IV lines and fluid therapy products, wearable CRI systems, and IT Solutions. Further, it provides telephony, nurse call, access control, CCTV, cordless, and Wi-Fi products. The company was formerly known as Citrofresh International Limited and changed its name to Paragon Care Limited in June 2008. Paragon Care Limited was incorporated in 1994 and is based in Melbourne, Australia.
IPO date
Oct 15, 1999
Employees
400
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT